{"id":22,"date":"2022-12-07T10:00:00","date_gmt":"2022-12-07T10:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=22"},"modified":"2025-09-02T08:42:43","modified_gmt":"2025-09-02T08:42:43","slug":"chinese-company-developed-anda-drug-products-approved-by-us-fda","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2022\/22.html","title":{"rendered":"[China BD 2022] Akeso and Summit Enters a 5 billion USD License on PD-1\/VEGF BsAbs Ivonescimab (AK112 \/ SMT112)"},"content":{"rendered":"\n<p>Announced Date: 2022-12-06 (December 06, 2022)<\/p>\n\n\n\n<p>Asset Name: Ivonescimab (AK112, SMT112)<\/p>\n\n\n\n<p>Licensor: Akeso Inc. (China)<\/p>\n\n\n\n<p>Licensee (Buyer):  Summit Therapeutics Inc. (US)<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality: BsAbs \uff08Bispecific antibody\uff09<\/p>\n\n\n\n<p>Asset Target:  PD-1 and VEGF<\/p>\n\n\n\n<p>Potential Indication:  non-small cell lung cancer (NSCLC)<\/p>\n\n\n\n<p>Current Stage: Phase 2<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority:<\/p>\n\n\n\n<p>Summit will receive the rights to develop and commercialize ivonescimab (SMT112) in the United States, Canada, Europe, and Japan. <\/p>\n\n\n\n<p>Akeso will retain development and commercialization rights for the rest of the regions including China.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Paymenet Detail:<\/p>\n\n\n\n<p>Upfront payment of\u00a0$500 million,<\/p>\n\n\n\n<p>Regulatory and commercial milestones of up to $4.5 billion,<\/p>\n\n\n\n<p>Total potential deal value is $5.0 billion.<\/p>\n\n\n\n<p>Low double-digit royalties on net sales.\u00a0<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p><a href=\"https:\/\/www.smmttx.com\/pressrelease\/summit-therapeutics-partners-with-akeso-inc-in-deal-for-up-to-5-billion-to-in-license-breakthrough-innovative-bispecific-antibody\/\">Summit Therapeutics Partners with Akeso Inc. in Deal for Up to $5 Billion to In-License Breakthrough Innovative Bispecific Antibody &#8211; Summit Therapeutics (smmttx.com)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2022-12-06 (December 06, 2022) Asset Name: Ivonescimab (AK112, SMT112) Licensor: Akeso Inc. (China) Licensee &hellip; <a title=\"[China BD 2022] Akeso and Summit Enters a 5 billion USD License on PD-1\/VEGF BsAbs Ivonescimab (AK112 \/ SMT112)\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2022\/22.html\"><span class=\"screen-reader-text\">[China BD 2022] Akeso and Summit Enters a 5 billion USD License on PD-1\/VEGF BsAbs Ivonescimab (AK112 \/ SMT112)<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-22","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/22","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=22"}],"version-history":[{"count":2,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/22\/revisions"}],"predecessor-version":[{"id":151,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/22\/revisions\/151"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=22"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=22"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=22"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}